Enanta Pharmaceuticals, Inc. Announces European Medicines Agency Validates Marketing Authorization Applications For AbbVie (ABBV)’s Investigational, All-Oral, Interferon-Free Regimen For Genotype 1 Chronic Hepatitis C
6/17/2014 11:31:59 AM
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced that AbbVie has reported that the Marketing Authorization Applications (MAAs) for AbbVie’s investigational, all-oral, interferon-free regimen primarily for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection have been fully validated and are now under accelerated assessment by the European Medicines Agency (EMA).
Help employers find you! Check out all the jobs and post your resume.
comments powered by